T
Taysha Gene Therapies
On a mission to eradicate monogenic CNS disease
About Taysha Gene Therapies
Taysha Gene Therapies is a clinical-stage biotechnology company that focuses on developing and commercializing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS). The company is dedicated to eradicating or treating severe and life-threatening monogenic diseases affecting the CNS.
Read full description
As a clinical-stage company, Taysha Gene Therapies is actively engaged in clinical trials to test the safety and efficacy of its therapeutic candidates. The company's business model is centered on the research and development of these gene therapies, with the ultimate goal of obtaining regulatory approval and bringing them to market. Its primary clients are patients suffering from these rare and severe neurological conditions. The company operates in the biotechnology and pharmaceutical market, a highly regulated and competitive industry.
At a glance
- Founded
- 2020
- Headquarters
- Dallas, United States
- Listing
- IPO 2020
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Research & analysis
Latest news
Press, funding announcements and product moves mentioning Taysha Gene Therapies.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
- PGPBM Capital Group
Nolan Capital
Series A10 investors entered at this stage
Fidelity Investments
BlackRock
Sands Capital Management
ArrowMark Partners
Octagon Capital Partners
Perceptive Advisors
Venrock
Invus
Casdin Capital
Franklin Templeton Investments
Series B and later5 investors entered at this stage
Standard Treasury
Silicon Valley Bank
Astellas Pharma
Trinity Capital
Capricorn Fund Managers
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Taysha Gene Therapies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Taysha Gene Therapies on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.